Desmoteplase: Phase III expanded

Lundbeck disclosed in its 1H12 earnings that it expanded enrollment to 480 from 400 patients to increase the power of the double-blind, placebo-controlled Phase III DIAS-3 trial evaluating 90 µg/kg IV...